Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients
International Journal of Surgical Pathology · 17.11.2026
DOI: 10.1177/10668969261495964 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Surgical Pathology, online erschienen am 17.11.2026. Verfasst von Yulin Haw und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gastrointestinal and Hepatic Pathology, Molecular Genetics, Emory University School of Medicine, Emory Winship Cancer Instit…. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
RSPO3 fusion activates the Wnt/β-catenin pathway at the level of upstream Wnt ligands, rather than directly through APC / CTNNB1 mutations. Beyond colorectal carcinoma, RSPO3 fusions remain underexplored. Herein, we report the first case series of PTPRK :: RSPO3 fusion-positive small intestinal adenocarcinoma. Among 115 genomically profiled small intestinal adenocarcinomas, 5 (4%) patients were identified, including 4 (80%) women and 1 (20%) man, aged 51 to 69 years (mean = 59), of African American (4/5; 80%) and White (1/5; 20%) ethnicity. Tumors arose from the jejunum (4/5; 80%) and duodenum (1/5; 20%), with a mean size of 4.7 cm. All tumors were adenocarcinoma, not otherwise specified, with mucinous features in 2/5 (40%), presenting at pT4 with lymphovascular and perineural invasion, and were mismatch repair-proficient/microsatellite stable, ERBB2 (HER2)-negative, and PD-L1 (CD274)-negative, with low tumor mutation burden and loss of heterozygosity. All fusion transcripts resulted from an in-frame PTPRK exon 1:: RSPO3 exon 2 fusion. The molecular landscape demonstrated frequent mutations in TP53 (5/5 [100%]) and the MAPK pathway genes ( KRAS , NRAS , BRAF ; 4/5 [80%]), while being APC / CTNNB1 / RNF43 -wild-type. Despite multimodal therapy, all patients developed metastasis (peritoneum 5/5 [100%]; liver 4/5 [80%]), with a mean overall survival of 28.5 months. PTPRK :: RSPO3 fusion defines a subset of small intestinal adenocarcinomas that shares a core molecular profile with its colorectal counterpart, exhibits aggressive behavior, and is a candidate for emerging Wnt-targeted therapies. Including RNA-based testing in the molecular profiling of small intestinal adenocarcinoma can identify rare yet targetable fusion genes that may inform patient selection for clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Gastrointestinal and Hepatic Pathology, Molecular Genetics, Emory University School of Medicine, Emory Winship Cancer Institute, Atlanta, GA, USA.
ORCID-Profile: Yulin Haw, Haider A Mejbel
Zitieren
APA
Haw, Y., Hsiao, W. Y., & Mejbel, H. A. (2026). Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients. International Journal of Surgical Pathology. https://doi.org/10.1177/10668969261495964
Vancouver
Haw Y, Hsiao WY, Mejbel HA. Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients. International Journal of Surgical Pathology. 2026. doi:10.1177/10668969261495964
BibTeX
@article{Haw2026,
author = {Haw, Yulin and Hsiao, Wen-Yu and Mejbel, Haider A},
title = {Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients},
journal = {International Journal of Surgical Pathology},
year = {2026},
doi = {10.1177/10668969261495964}
}
EUVIMED